Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2001, p. 871-878, Vol. 39, No. 3
Division of AIDS, STD, and TB Laboratory
Research, National Center for Infectious Diseases, Centers for
Disease Control and Prevention, Atlanta, Georgia 30333
Received 14 September 2000/Returned for modification 29 November
2000/Accepted 31 December 2000
We have developed an amplification-based reverse dot blot assay for
the detection of specific sites of insertion of the Mycobacterium tuberculosis insertion sequence IS6110. In this
assay, a set of biotin-labeled amplicons representing the various
copies of IS6110 and their flanking sequences is generated
by linker-mediated PCR. The amplicons are then hybridized to
immobilized oligonucleotide probes that are specific for known
IS6110 insertion sites. The method was evaluated using an
array of oligonucleotide probes corresponding to IS6110
insertion sites from M. tuberculosis strains CDC1551,
Erdman, and H37Rv, and multidrug-resistant strain W. A set of 72 DNA
samples from 60 M. tuberculosis clinical isolates was
analyzed for the presence or absence of these insertion sites, and the
assay was found to be highly reproducible. This method of identifying
insertion sites has been named "insite" and can be used for the
genotyping of M. tuberculosis complex strains based on
IS6110 insertion site profiles.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.3.871-878.2001
Reverse Dot Blot Assay (Insertion Site Typing) for
Precise Detection of Sites of IS6110 Insertion in the
Mycobacterium tuberculosis Genome
*
Corresponding author. Mailing address: Mailstop F08,
NCID/DASTLR, CDC, 1600 Clifton Rd., Atlanta, GA 30333. Phone: (404)
639-1281. Fax: (404) 639-1287. E-mail: JCrawford{at}cdc.gov.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»